Bortezomib (VELCADE), Cladribine and Rituximab (VCR) in Mantle Cell Lymphoma: A Phase I/II Study (PSHCI 10-011)
Active, no longer recruiting
Phase of Trial: Phase I
Latest Information Update: 09 Aug 2017
At a glance
- Drugs Bortezomib (Primary) ; Cladribine (Primary) ; Rituximab (Primary)
- Indications Mantle-cell lymphoma
- Focus Adverse reactions
- 06 Aug 2017 Study phase changed from phase I/II to only phase I.
- 04 Aug 2017 Planned End Date changed from 1 Jul 2017 to 1 Aug 2020.
- 04 Aug 2017 Planned primary completion date changed to 1 Aug 2018.